The anti-HIV drug saquinavir (Invirase), a protease inhibitor, is used with a small amount of another protease inhibitor, ritonavir (Norvir), as part of combination therapy for HIV infection. In general, saquinavir-based regimens are well tolerated.
From Canadian AIDS Treatment Information Exchange (CATIE). For more information visit CATIE's Information Network at http://www.catie.ca
After successive HIV vaccine trial failures in 2008, there is now broad agreement that more, not less, basic and early-stage clinical research is needed. Further, the 2009 results of the RV144 Phase III HIV Vaccine Trial provide evidence that a safe and effective HIV vaccine is possible.
With this backdrop, CIHR is pleased to launch the Canadian HIV Vaccine Initiative (CHVI) Team Grant funding opportunity which will support internationally recognized teams of Canadian and Low and Middle Income Country (LMIC) researchers in their efforts to contribute important knowledge to the global search for HIV vaccines.
The funding will support teams that are multidisciplinary in nature, or that are composed of entirely social scientists or basic scientists, and develop the next generation of HIV vaccine researchers in Canada and in LMICs. This $17M funding opportunity -- supported by CIHR and its partner the Canadian International Development Agency (CIDA) -- will fund at least four teams in 2011.
For more information, please see the CHVI funding opportunity.
